Bio-manufacturing comes to Boston
A group of Boston-based universities, hospitals, and corporations are announcing today that they're joining forces to build a new bio-manufacturing center for cell therapies, STAT’s Sharon Begley writes. The idea is that the manufacturing site, projected to open by 2022, can help cement Boston’s leadership in the industry.
More broadly, the industry needs additional manufacturing capacity as cell therapies become more common. The supply chain as it exists can be fraught, as many of these medicines can be bespoke and require cells from individual patients. Other cellular drugs, including gene therapies, require biological molecules to be manufactured en masse.
Right now, the bulk of such work is done by contract manufacturing organizations, but they’re working at capacity.
More broadly, the industry needs additional manufacturing capacity as cell therapies become more common. The supply chain as it exists can be fraught, as many of these medicines can be bespoke and require cells from individual patients. Other cellular drugs, including gene therapies, require biological molecules to be manufactured en masse.
Right now, the bulk of such work is done by contract manufacturing organizations, but they’re working at capacity.
No hay comentarios:
Publicar un comentario